Clinical trials: Pancreas Cancer
Pancreatic Cancer
Administration of GRASPA (Suspension of Erythrocytes Encapsulating L-asparaginase)in Patients With Pancreatic Cancer
The interest in using L-asparaginase in pancreatic cancer arose from in vitro and in vivo studies data showing an anti-neoplastic effect on pancreatic tumor cell lines.
- Trial name
- NCT01523808
- Testing
- GRASPA
- Volunteers
- 12 people
- Sponsor
- ERYtech Pharma
Neoplasms, Pancreatic Neoplasms
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Background: LMB-100 is a man-made protein designed to kill cancer cells. LMB-100 targets a cancer marker called mesothelin. Mesothelin is found on the surface of many different tumors, including pancreatic cancer, but is made by…
- Trial name
- NCT02810418
- Testing
- LMB-100, Nab-Paclitaxel, Mesothelin Expression
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of RMC-4630 and cobimetinib in adult participants with relapsed/refractory solid tumors with specific…
- Trial name
- NCT03989115
- Testing
- RMC-4630, Cobimetinib, Drug: Osimertinib
- Where
- 24 sites in United States, South Korea
- Volunteers
- 113 people
- Sponsor
- Revolution Medicines, Inc.
Liver Cancer, Pancreatic Cancer
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas
The goal of this clinical research study is to learn if there is a difference in patients' quality of recovery if they receive 1 of 2 standard kinds of pain control treatments after surgery on the liver and/or pancreas.
- Trial name
- NCT01438476
- Testing
- Intravenous Patient-Controlled Analgesia (IVPCA), Thoracic Epidural Analgesia (TEA), Questionnaires
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- M.D. Anderson Cancer Center
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.
- Conditions
- Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
- Trial name
- NCT03138720
- Testing
- Paclitaxel Protein Bound (Abraxane)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer
Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients
Study of multi-tracer PET scans to assess response to gemcitabine in pancreatic cancer
- Trial name
- NCT02245217
- Testing
- PET/CT scan to assess treatment efficacy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Utah
Carcinoma, Islet Cell, Carcinoma, Pancreas
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
This study randomized patients with advanced pancreatic islet cell tumors to receive either sunitinib or placebo. Patients who were randomized to sunitinib received 37.5 mg of sunitinib daily, those randomized to placebo received…
- Trial name
- NCT00428597
- Testing
- sunitinib malate
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Pancreas Cancer
A Supervised Prehabilitation Program for Patients With Pancreatic Cancer
The purpose of this study is to assess the use of an exercise program in people with pancreatic cancer.
- Trial name
- PREHAB (NCT05692323)
- Testing
- PREHAB
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Cedars-Sinai Medical Center
Gastrointestinal Cancers, Cholangiocarcinoma
Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Prospective, multi-center, open label, non-randomized clinical trial to assess efficacy of [18F]FAPI-74 to detect FAP expressing cells in patients diagnosed with gastrointestinal cancers, including hepatocellular carcinoma…
- Conditions
- Gastrointestinal Cancers, Cholangiocarcinoma, Gastric Cancer, Colorectal Cancer
- Trial name
- 18F-FAPI-74 GI (NCT05641896)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 6 sites in United States
- Volunteers
- 112 people
- Sponsor
- SOFIE
Adenocarcinoma of the Pancreas
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
- Trial name
- NCT03490760
- Testing
- Durvalumab, Radiation Therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Baptist Health South Florida
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Pancreatic Endocrine Neoplasms
An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
A single institutional study of Pancreatic Endocrine Neoplasms over 18 years.
- Trial name
- NCT02400996
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Medical College and Hospital Kolkata
Pancreatic Cancer
Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer
The current trial will provide important data on the recurrence rates and patterns of failure using state of the art target agent, chemotherapy and proton beam technology for patients with Locally Advanced Pancreatic Cancer…
- Trial name
- NCT01683422
- Testing
- Proton, Gemcitabine, Erlotinib, Capecitabine, Proton Radiation
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Loma Linda University
Pancreatic Cancer
Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00625586
- Testing
- RAV12, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- MacroGenics
KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7
Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations
This phase II trial studies how well selumetinib sulfate works in treating patients with pancreatic cancer with Kirsten rat sarcoma (KRAS) G12R mutations that has spread from where it started to nearby tissue or lymph nodes or…
- Conditions
- KRAS NP_004976.2:p.G12R, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT03040986
- Testing
- Laboratory Biomarker Analysis, Selumetinib Sulfate
- Where
- 9 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Michigan Genetic Hereditary Testing (MiGHT)
The primary purpose of this study is to compare three interventions, two experimental and one standard of care (usual care), to see if the experimental interventions will increase the likelihood of a participant obtaining…
- Conditions
- Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- MiGHT (NCT05162846)
- Testing
- Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
- Where
- United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Pain, Bladder Cancer
Study of D-Methadone in Patients With Chronic Pain
The purpose of this study is to determine the safest dose of d-methadone that can be given, without causing severe side effects in most patients with chronic pain.
- Conditions
- Pain, Bladder Cancer, Breast Cancer, CNS Cancer
- Trial name
- NCT00588640
- Testing
- d-Methadone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
The purpose of this study is evaluate the efficacy and safety of FOLFIRINOX in patients with gastroenteropancreatic high-grade neuroendocrine carcinomas.
- Conditions
- Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
- Trial name
- NCT03042780
- Testing
- FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Cancer
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine.
- Trial name
- NCT02080260
- Testing
- regorafenib
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences